

Cereno Scientific announces a Capital Markets Day 2022

Cereno Scientific (XSAT: CRNO B) today announced that the company's inaugural Capital Markets Day will be held on August 30, 2022. We invite analysts, investors, and financial media to join us for insights into our strategy and operations.

The Capital Markets Day will be held on Tuesday, August 30, 2022, at 14:30-17:30 in central Stockholm. The program will start at 15:00, with coffee being served before. The Capital Markets Day will be held at Helio GT30, Grev Turegatan 30, in Stockholm.

The program will provide an update on Cereno's pipeline, clinical and preclinical development, and growth strategy from both the company as well as external collaborators. A detailed agenda will be provided ahead of time.

Register for the event onsite or online

We hope you can join the Capital Markets Day in-person in Stockholm. Limited seats are available onsite and will be reserved on a first-come-first-served basis. For those not able to join onsite, the Capital Markets Day will be live streamed on Cereno's website and recorded for on-demand viewing. Those who participate online will be able to submit their questions online.

To participate, onsite or online, please register by completing the form on <https://tv.streamfabriken.com/cereno-scientific-cmd-2022>.

For further information, please contact:

Daniel Brodén, CFO

Phone: +46 768 66 77 87

Email: info@cerenoscientific.com

<http://www.cerenoscientific.com/>

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a stable,

selective, and potent prostacyclin receptor agonist. It has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.